Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease

MT Newswires Live

07/10

Serina Therapeutics (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group.

The company said additional patient dosing in cohort 1 of the study is now taking place at clinical sites in the US and Australia.

Serina said it now expects to complete enrollment and dosing of cohort 1 ahead of its previous guidance to finish by the end of Q3.

SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation, which has been known to reduce the severity of levodopa-related motor complications in Parkinson's disease, the company said.

Shares of Serina Therapeutics rose more than 9% in Thursday trading.

Price: 2.19, Change: +0.19, Percent Change: +9.50

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2650754409"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2650754409\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2650754409?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 00:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650754409","market":"sh","top_or_hot":-1,"title":"Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease","media":"MT Newswires Live","content":"<html><body><p> Serina <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group.</p><p>The company said additional patient dosing in cohort 1 of the study is now taking place at clinical sites in the US and Australia.</p><p>Serina said it now expects to complete enrollment and dosing of cohort 1 ahead of its previous guidance to finish by the end of Q3.</p><p>SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation, which has been known to reduce the severity of levodopa-related motor complications in Parkinson's disease, the company said.</p><p>Shares of Serina Therapeutics rose more than 9% in Thursday trading.</p><p>Price: 2.19, Change: +0.19, Percent Change: +9.50</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSerina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-10 00:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Serina <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group.</p><p>The company said additional patient dosing in cohort 1 of the study is now taking place at clinical sites in the US and Australia.</p><p>Serina said it now expects to complete enrollment and dosing of cohort 1 ahead of its previous guidance to finish by the end of Q3.</p><p>SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation, which has been known to reduce the severity of levodopa-related motor complications in Parkinson's disease, the company said.</p><p>Shares of Serina Therapeutics rose more than 9% in Thursday trading.</p><p>Price: 2.19, Change: +0.19, Percent Change: +9.50</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SER.AU","symbol_name":"STRATEGIC ENERGY RESOURCES","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650754409","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650754409","pubTimestamp":1783615201,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Serina Therapeutics  said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group.The company said additional patient dosing in cohort 1 of the study is now taking place at clinical sites in the US and Australia.Serina said it now expects to complete enrollment and dosing of cohort 1 ahead of its previous guidance to finish by the end of Q3.SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation, which has been known to reduce the severity of levodopa-related motor complications in Parkinson's disease, the company said.Shares of Serina Therapeutics rose more than 9% in Thursday trading.Price: 2.19, Change: +0.19, Percent Change: +9.50","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SER.AU":"STRATEGIC ENERGY RESOURCES","SER":"Serina Therapeutics, Inc.","BK4139":"生物科技","BK7095":"多种金属与采矿"},"translate_title":"Serina 表示，专家组批准在 SER-252 治疗帕金森病的 1b 期试验中给更多患者注射剂量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SER":1.5,"SER.AU":1},"content_text":"Serina Therapeutics (SER) said Thursday the independent safety monitoring committee for its phase 1b trial of SER-252 in patients with advanced Parkinson's disease recommended dosing additional patients after a review of the initial 72-hour safety and tolerability data from the sentinel dosing group.The company said additional patient dosing in cohort 1 of the study is now taking place at clinical sites in the US and Australia.Serina said it now expects to complete enrollment and dosing of cohort 1 ahead of its previous guidance to finish by the end of Q3.SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation, which has been known to reduce the severity of levodopa-related motor complications in Parkinson's disease, the company said.Shares of Serina Therapeutics rose more than 9% in Thursday trading.Price: 2.19, Change: +0.19, Percent Change: +9.50","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}